АРТЕРИАЛЬНЫЕ РЕНТГЕНЭНДОВАСКУЛЯРНЫЕ МЕТОДЫ ЛЕЧЕНИЯ НЕРЕЗЕКТАБЕЛЬНОЙ ВНУТРИПЕЧЕНОЧНОЙ ХОЛАНГИОКАРЦИНОМЫ (ОБЗОР ЛИТЕРАТУРЫ И КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ)
Open Access
- 18 October 2024
- journal article
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Visualization in Medicine
- Vol. 6 (2) , 30-37
Abstract
Холангиоцеллюлярный рак является вторым по распространенности первичным злокачественным новообразованием печени. Радикальное удаление опухоли возможно лишь у 30–40% больных. Системная химиотерапия (СХТ) — основной метод лечения нерезектабельной внутрипеченочной холангиокарциномы (ХКЦ), однако частота объективного ответа не превышает40%, а медиана выживаемости составляет 12 месяцев. Артериальные рентгенэндоваскулярные методы могут являться альтернативой СХТ у неоперабельных больных. В обзоре представлены данные литературы и собственный опыт применения методов регионарной химиотерапии нерезектабельной внутрипеченочной ХКЦ. Cholangiocellular carcinoma is the second most common primary liver malignancy. Radical resection is possible only in 30–40% sick. Systemic chemotherapy (SCT) is the basic treatment for unresectable intrahepatic cholangiocarcinoma (ICC), but the objective response rate does not exceed 40%, and the median survival is no more than 12 months. Arterial endovascular methods may be an alternative treatment to SCT. The review presents literature data and our experience in the use of regional chemotherapy in unresectable ICC.Keywords
This publication has 22 references indexed in Scilit:
- Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world dataLiver International, 2023
- EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinomaJournal of Hepatology, 2023
- The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World StudyCanadian Journal of Gastroenterology and Hepatology, 2022
- Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter studyExpert Review of Gastroenterology & Hepatology, 2021
- Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysisCancer Treatment Reviews, 2021
- Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialAnnals of Oncology, 2019
- Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomesCancer, 2019
- Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trialAnnals of Oncology, 2019
- Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues OncologuesCancer, 2015
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010